101 related articles for article (PubMed ID: 16594642)
1. Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia.
Jin F; Tayab ZR; Balthasar JP
AAPS J; 2006 Jan; 7(4):E895-902. PubMed ID: 16594642
[TBL] [Abstract][Full Text] [Related]
2. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
Blood; 2002 Sep; 100(6):2087-93. PubMed ID: 12200371
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura.
Hansen RJ; Balthasar JP
J Pharmacol Exp Ther; 2001 Jul; 298(1):165-71. PubMed ID: 11408538
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia.
Deng R; Balthasar JP
J Pharm Sci; 2007 Jun; 96(6):1625-37. PubMed ID: 17238194
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions.
Getman KE; Balthasar JP
J Pharm Sci; 2005 Apr; 94(4):718-29. PubMed ID: 15682382
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia.
Deng R; Balthasar JP
Blood; 2007 Mar; 109(6):2470-6. PubMed ID: 17132715
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.
Crow AR; Yu H; Han D; Lazarus AH
PLoS One; 2013; 8(8):e71882. PubMed ID: 23940791
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
Gold HK; Gimple LW; Yasuda T; Leinbach RC; Werner W; Holt R; Jordan R; Berger H; Collen D; Coller BS
J Clin Invest; 1990 Aug; 86(2):651-9. PubMed ID: 2384607
[TBL] [Abstract][Full Text] [Related]
10. Investigation of antibody-coated liposomes as a new treatment for immune thrombocytopenia.
Deng R; Balthasar JP
Int J Pharm; 2005 Nov; 304(1-2):51-62. PubMed ID: 16171959
[TBL] [Abstract][Full Text] [Related]
11. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody.
Bazin R; Lemieux R; Tremblay T
Br J Haematol; 2006 Oct; 135(1):97-100. PubMed ID: 16925577
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency.
Salerno SN; Deng R; Kakkar T
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1316-1327. PubMed ID: 35860862
[TBL] [Abstract][Full Text] [Related]
14. Angiographic evaluation of middle cerebral artery reperfusion caused by platelet glycoprotein IIb/IIIa receptor complex antagonist murine 7E3 F(ab')2 in a model of focal cerebral ischemia in rats.
Yang Y; Li Q; Nakada MT; Yang T; Shuaib A
J Neurosurg; 2001 Apr; 94(4):582-8. PubMed ID: 11302656
[TBL] [Abstract][Full Text] [Related]
15. Heparin-induced thrombocytopenia and other immune thrombocytopenias: lessons from mouse models.
McKenzie SE; Reilly MP
Semin Thromb Hemost; 2004 Oct; 30(5):559-68. PubMed ID: 15497098
[TBL] [Abstract][Full Text] [Related]
16. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.
Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR
Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295
[TBL] [Abstract][Full Text] [Related]
17. Passive neonatal thrombocytopenia. A case study of factors predicting the response to i.v. IgG therapy.
Katikaneni LD; Rao KP; Lazarchick J
Ann Clin Lab Sci; 1989; 19(4):255-9. PubMed ID: 2757353
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?
Crow AR; Song S; Suppa SJ; Ma S; Reilly MP; Andre P; McKenzie SE; Lazarus AH
Blood; 2011 Jan; 117(3):971-4. PubMed ID: 21045192
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.
Hansen RJ; Balthasar JP
Thromb Haemost; 2002 Dec; 88(6):898-9. PubMed ID: 12529736
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
